- Citing its intent to focus its resources on it ENHANZE drug delivery technology, Halozyme Therapeutics (HALO +1.1%) will terminate development of PEGPH20, shut down its oncology operations and cut 160 jobs representing ~55% of its workforce. Most (~80%) of the layoffs will be done by early January 2020.
- Management says the restructuring and cost-saving initiatives should save $130M - 140M next year, adding that it expects to be "sustainably profitable" in Q2 2020.
- The company will provide further details during its Q3 conference call on November 12.
Halozyme bails on PEGPH20; to cut headcount 55%
Recommended For You
About HALO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
HALO | - | - |
Halozyme Therapeutics, Inc. |